Cancer gets a sting with new discovery

November 8, 2018, GlaxoSmithKline
Credit: CC0 Public Domain

Today a paper authored by 44 scientists was published in the scientific journal Nature, reporting a potential new class of immunotherapy drugs to treat some of the most common cancers. The study shows how these molecules work and what they might mean for the future of cancer treatment.

Using the immune system to fight cancer

The immune system is a complex network of that work together to prevent infection, illness and disease. The cells that make up the immune system can detect thousands of triggers, from viruses to parasitic worms, known as pathogens. Importantly, immune cells can tell the difference between the body's own cells and foreign cells or material. Once the immune cells lock down on their target, they fine-tune a response to destroy the invading pathogen.

It's a powerful network, and scientists have been looking at new ways of using the immune system to fight cancer and to answer the question: Can we train the immune system to identify as their target and flag them for destruction?

A protein with a sting in its tail

One of the proteins that piqued the scientists' interest is called STING. When active, it triggers the body to release a subset of T-cells that are capable of recognising and destroying cancer cells. But can it be activated?

In the paper published today, the scientists describe their work to find new molecules to activate STING.

Joshi Ramanjulu, senior director of medicinal chemistry and lead author on the study, says, "Finding a molecule that is a match with the protein you're looking for is a difficult process. We've been studying STING for a number of years to learn more about how it works and what it causes in the cell. Through screening multiple libraries of molecules, we found a family of molecules that showed promising activity, and by tweaking their properties, made them a more efficient activator of the STING protein."

These molecules are the first of their kind and work differently to some of the other STING activators that are being developed.

Joshi explains: "One of the potential advantages of these new molecules is they can be given by injection into the bloodstream as opposed to directly into a tumour, which can be tricky. They can potentially reach inaccessible solid tumours and clumps of cancer cells that have broken away from the main tumour, which could potentially expand the options for patients. We also saw in mouse models of cancer that the new molecules activated the immune system 'memory,' meaning that if the cancer was to come back, then the were primed and ready to attack without needing more treatment."

Unlocking STING's potential

The scientists are excited about the potential of these new molecules, but acknowledge that this is early research and many years away from becoming an approved treatment. The molecules in this paper have not yet been tested in patients and are not approved for use by any regulatory authority.

"We'll keep studying STING activators as potential treatments. The next step for us will be to move into human safety studies of the , which we expect to start in 2019. The biology of STING is really interesting, so we are also exploring the effects of switching STING on as a way of boosting response to vaccines and how switching STING off could be a potential treatment route for some autoimmune diseases such as lupus," Joshi added.

Explore further: The STING of death in T cells

More information: Joshi M. Ramanjulu et al. Design of amidobenzimidazole STING receptor agonists with systemic activity, Nature (2018). DOI: 10.1038/s41586-018-0705-y

Related Stories

The STING of death in T cells

September 5, 2017
The cells of the innate immune system use a signaling pathway comprising STING (Stimulator of interferon genes) to detect DNA from invading viruses and fight them. However, it is unknown if STING triggers the same or different ...

New small molecules for the treatment of autoinflammatory diseases

July 5, 2018
EPFL scientists have discovered two small-molecule compound series that can effectively block a central pathway of the innate immune system, offering a promising new way for treating autoinflammatory diseases. The study is ...

How our immune system detects broken DNA

September 6, 2018
Our immune system is working every day to protect us from bacteria, viruses, and parasites, but it can also detect when our own cells are damaged.

Tumour immune cells could aid cancer therapies, study shows

November 7, 2018
A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests.

Danish discovery opens up for new type of immunological treatment of cancer

February 21, 2017
Researchers from Aarhus University have found an important piece of the puzzle leading towards an understanding of how our innate immune system reacts against viral infections and recognises foreign DNA, for example from ...

Researchers describe role of STING protein in development of colorectal cancer

January 1, 2016
A new study published today by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine (Sylvester) reports on a key finding about the immune system's response to tumor development ...

Recommended for you

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Fecal transplant effective against immunotherapy-induced colitis

November 12, 2018
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs). The study from The University ...

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

Suicide handshakes kill precursor T cells that pose autoimmune dangers

November 12, 2018
Ball lands in cup; cup triggers spring; spring clamps lever onto ball and holds it tight. That's a rough description of newly discovered cellular mechanisms that eliminate T cells that may cause autoimmune disorders.

Research brings personalized medicine to treat leukemia one step closer

November 12, 2018
Scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers in a study that was the culmination of a decade's research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.